Fadavi Pedram, Nafisi Nahid, Hariri Ramyar, Novin Kambiz, Sanei Mastaneh, Razzaghi Zahra, Arefpour Amirmohammad, Garousi Maryam
Department of Radiation Oncology, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.
Department of General Surgery, Hazrat-e Rasool General Hospital, Iran University of Medical Sciences, Tehran, Iran.
Med J Islam Repub Iran. 2021 Dec 6;35:162. doi: 10.47176/mjiri.35.162. eCollection 2021.
Breast cancer is one of the most common cancers. Researchers are trying to diagnose the disease through easier and safer methods. Serum markers such as ferritin and vitamin D level would be very helpful. This research could pave the way for more comprehensive studies on how to use this serum factor in breast cancer screening, as well as early detection of the disease in its early stages. This study consisted of two groups, the first group comprising patients diagnosed with breast cancer before undergoing any treatment and the second group as control were healthy people. Serum ferritin and vitamin D levels were measured. Pathological information of the patient's tumor, including ER, HER2, KI67, lymphovascular invasion, and disease stage, were collected as well. Data were analyzed by IBM SPSS advanced statistics version 23.0 (SPSS Inc., Chicago, IL). P-value of ≤0.05 was considered significant. Eighty-eight subjects were enrolled in this study, 29 (33%) breast cancer patients and 59 (67%) healthy women. In breast cancer patients, serum ferritin levels were 106.55±111.25, which were higher than healthy women's serum ferritin 52.71±36.95 (p=0.083). Furthermore, 18 (66.7%) of breast cancer patients and 55 (93.2%) of healthy women had low serum ferritin levels (p=0.001). 3 (11.1%) patients in the cancer group had serum vitamin D deficiency, while all subjects in the control group had serum vitamin D higher than 10 ng/dl (p =0.009). The results of this study showed a correlation between breast cancer and vitamin D deficiency, and elevated ferritin. Perhaps with further studies, there could be a role in predicting the prognosis and screening of breast cancer for these associations.
乳腺癌是最常见的癌症之一。研究人员正试图通过更简便、更安全的方法来诊断这种疾病。血清标志物如铁蛋白和维生素D水平会非常有帮助。这项研究可为关于如何在乳腺癌筛查中使用这种血清因子以及在疾病早期进行早期检测的更全面研究铺平道路。 本研究分为两组，第一组包括在接受任何治疗前被诊断为乳腺癌的患者，第二组作为对照组为健康人。测量血清铁蛋白和维生素D水平。还收集了患者肿瘤的病理信息，包括雌激素受体（ER）、人表皮生长因子受体2（HER2）、增殖细胞核抗原（KI67）、淋巴管侵犯和疾病分期。数据采用IBM SPSS高级统计版本23.0（SPSS公司，伊利诺伊州芝加哥）进行分析。P值≤0.05被认为具有统计学意义。 本研究共纳入88名受试者，其中29名（33%）为乳腺癌患者，59名（67%）为健康女性。乳腺癌患者的血清铁蛋白水平为106.55±111.25，高于健康女性的血清铁蛋白水平52.71±36.95（p=0.083）。此外，18名（66.7%）乳腺癌患者和55名（93.2%）健康女性的血清铁蛋白水平较低（p=0.001）。癌症组中有3名（11.1%）患者存在血清维生素D缺乏，而对照组所有受试者的血清维生素D均高于10 ng/dl（p =0.009）。 本研究结果显示乳腺癌与维生素D缺乏以及铁蛋白升高之间存在相关性。也许通过进一步研究，这些关联在预测乳腺癌预后和筛查方面可能会发挥作用。
